Search Results - "The lancet oncology"

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial by Saito, Haruhiro, Fukuhara, Tatsuro, Furuya, Naoki, Watanabe, Kana, Sugawara, Shunichi, Iwasawa, Shunichiro, Tsunezuka, Yoshio, Yamaguchi, Ou, Okada, Morihito, Yoshimori, Kozo, Nakachi, Ichiro, Gemma, Akihiko, Azuma, Koichi, Kurimoto, Futoshi, Tsubata, Yukari, Fujita, Yuka, Nagashima, Hiromi, Asai, Gyo, Watanabe, Satoshi, Miyazaki, Masaki, Hagiwara, Koichi, Nukiwa, Toshihiro, Morita, Satoshi, Kobayashi, Kunihiko, Maemondo, Makoto

“…Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive…”
Get full text

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China by Liang, Wenhua, Guan, Weijie, Chen, Ruchong, Wang, Wei, Li, Jianfu, Xu, Ke, Li, Caichen, Ai, Qing, Lu, Weixiang, Liang, Hengrui, Li, Shiyue, He, Jianxing

“…[...]patients who underwent chemotherapy or surgery in the past month had a numerically higher risk (three [75%] of four patients) of clinically severe events…”
Get full text

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study by Marabelle, Aurélien, Fakih, Marwan, Lopez, Juanita, Shah, Manisha, Shapira-Frommer, Ronnie, Nakagawa, Kazuhiko, Chung, Hyun Cheol, Kindler, Hedy L, Lopez-Martin, Jose A, Miller, Wilson H, Italiano, Antoine, Kao, Steven, Piha-Paul, Sarina A, Delord, Jean-Pierre, McWilliams, Robert R, Fabrizio, David A, Aurora-Garg, Deepti, Xu, Lei, Jin, Fan, Norwood, Kevin, Bang, Yung-Jue

“…Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of…”
Get full text

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial by Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno

“…Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2…”
Get full text

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study by Maringe, Camille, Spicer, James, Morris, Melanie, Purushotham, Arnie, Nolte, Ellen, Sullivan, Richard, Rachet, Bernard, Aggarwal, Ajay

“…Since a national lockdown was introduced across the UK in March, 2020, in response to the COVID-19 pandemic, cancer screening has been suspended, routine…”
Get full text

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial by Bahadoer, Renu R, Dijkstra, Esmée A, van Etten, Boudewijn, Marijnen, Corrie A M, Putter, Hein, Kranenbarg, Elma Meershoek-Klein, Nagtegaal, Iris D, Beets-Tan, Regina G H, Blomqvist, Lennart K, Fokstuen, Tone, Capdevila, Jaume, Cervantes, Andrés, Glimelius, Bengt, Østergaard, L., Svendsen Jensen, F., Pfeiffer, P., Jensen, K.E.J., Schreurs, W.H., van der Vliet, J.J., Bruynzeel, A.M.E., Kerver, E.D., van Leerdam, M.E., Tanis, P.J., Bleeker, W.A., Ten Tije, A.J., Immink, J.M., Marinelli, A.W.K.S., Ceha, H.M., Bekker, J.H.M., Creemers, G.J., Nieuwenhuijzen, G.A.P., van den Berg, H., van der Deure, W.M., Olieman, A.F.T., van den Bergh, A.C.M., de Groot, D.J.A., Havenga, K., Beukema, J.C., Vanstiphout, J.W.P., de Valk, B., Eijsbouts, Q.A.J., Polée, M.B., Hoff, C., Peters, F.P., Radema, S.A., de Wilt, H., Braam, P., Veldhuis, G.J., Hess, D., Rozema, T., Reerink, O., Pronk, A., Vos, J., Tascilar, M., Patijn, G.A., Kersten, C., Mjåland, O., Nesbakken, A.N., Benedik, J., Velenik, V., Capdevila, J., Espin, E., Salazar, R., Biondo, S., die Trill, J., Aparicio, J., Garcia Granero, E., Safont, M.J., Cervantes, A., Espí Macías, A., Malmberg, L., Dafnis, G., Berglund, A., Österlund, L., Kovacs, K., Hol, J., Ottosson, S., Carlsson, G., Bratthäll, C., Assarsson, J., Lödén, B.L., Hede, P., Verbiené, I., Hallböök, O., Johnsson, A., Lydrup, M.L., Villmann, K., Matthiessen, P., Haux, J., Skullman, S., Holm, T., Flygare, P., Walldén, M., Lundberg, O., Radu, C., Påhlman, L., Palenius, U., Parinkh, P., Kim, H., Silviera, M.L.

“…Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the…”
Get full text

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study by Ren, Zhenggang, Xu, Jianming, Bai, Yuxian, Xu, Aibing, Cang, Shundong, Du, Chengyou, Li, Qiu, Lu, Yinying, Chen, Yajin, Guo, Yabing, Chen, Zhendong, Liu, Baorui, Jia, Weidong, Wu, Jian, Wang, Junye, Shao, Guoliang, Zhang, Bixiang, Shan, Yunfeng, Meng, Zhiqiang, Wu, Jianbing, Gu, Shanzhi, Yang, Wei, Liu, Chao, Shi, Xuetao, Gao, Zhenyuan, Yin, Tao, Cui, Jiuwei, Huang, Ming, Xing, Baocai, Mao, Yilei, Teng, Gaojun, Qin, Yanru, Wang, Jinhai, Xia, Feng, Yin, Guowen, Yang, Yong, Chen, Mingxia, Wang, Yan, Zhou, Hui, Fan, Jia

“…China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma…”
Get full text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial by West, Howard, McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J, Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Sandler, Alan, Lin, Wei, Ochi Lohmann, Tania, Archer, Venice, Wang, Lijia, Kowanetz, Marcin, Cappuzzo, Federico

“…Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated…”
Get full text

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial by Schmid, Peter, Rugo, Hope S, Adams, Sylvia, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Maiya, Vidya, Husain, Amreen, Winer, Eric P, Loi, Sherene, Emens, Leisha A

“…Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim…”
Get full text

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study by Monin, Leticia, Laing, Adam G, Muñoz-Ruiz, Miguel, McKenzie, Duncan R, del Molino del Barrio, Irene, Alaguthurai, Thanussuyah, Domingo-Vila, Clara, Hayday, Thomas S, Graham, Carl, Seow, Jeffrey, Abdul-Jawad, Sultan, Kamdar, Shraddha, Harvey-Jones, Elizabeth, Graham, Rosalind, Cooper, Jack, Khan, Muhammad, Vidler, Jennifer, Kakkassery, Helen, Sinha, Shubhankar, Davis, Richard, Dupont, Liane, Francos Quijorna, Isaac, O'Brien-Gore, Charlotte, Lee, Puay Ling, Eum, Josephine, Conde Poole, Maria, Joseph, Magdalene, Davies, Daniel, Wu, Yin, Swampillai, Angela, North, Bernard V, Montes, Ana, Harries, Mark, Rigg, Anne, Spicer, James, Malim, Michael H, Fields, Paul, Patten, Piers, Di Rosa, Francesca, Papa, Sophie, Tree, Timothy, Doores, Katie J, Hayday, Adrian C, Irshad, Sheeba

“…The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the…”
Get full text

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial by Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García-Campelo, María Rosario, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas Antón, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Romero, Atocha, Massuti, Bartomeu, Cruz-Bermúdez, Alberto

“…Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of…”
Get full text

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial by Kato, Ken, Cho, Byoung Chul, Takahashi, Masanobu, Okada, Morihito, Lin, Chen-Yuan, Chin, Keisho, Kadowaki, Shigenori, Ahn, Myung-Ju, Hamamoto, Yasuo, Doki, Yuichiro, Yen, Chueh-Chuan, Kubota, Yutaro, Kim, Sung-Bae, Hsu, Chih-Hung, Holtved, Eva, Xynos, Ioannis, Kodani, Mamoru, Kitagawa, Yuko

“…Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our…”
Get full text

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial by Kang, Yoon-Koo, Chen, Li-Tzong, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Chung, Hyun Cheol, Lee, Keun-Wook, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Chung, Ik-Joo, Yamaguchi, Kensei, Kato, Ken, Sym, Sun Jin, Kadowaki, Shigenori, Tsuji, Kunihiro, Chen, Jen-Shi, Bai, Li-Yuan, Oh, Sung-Yong, Choda, Yasuhiro, Yasui, Hisateru, Takeuchi, Kentaro, Hirashima, Yoshinori, Hagihara, Shunsuke, Boku, Narikazu

“…The additive or synergistic sustained antitumour effect of immune checkpoint inhibitors in combination with oxaliplatin-based chemotherapy has previously been…”
Get full text

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial by O’Brien, Mary, Paz-Ares, Luis, Marreaud, Sandrine, Dafni, Urania, Oselin, Kersti, Havel, Libor, Esteban, Emilio, Isla, Dolores, Martinez-Marti, Alex, Faehling, Martin, Tsuboi, Masahiro, Lee, Jong-Seok, Nakagawa, Kazuhiko, Yang, Jing, Samkari, Ayman, Keller, Steven M, Mauer, Murielle, Jha, Nitish, Stahel, Rolf, Besse, Benjamin, Peters, Solange

“…Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected…”
Get full text

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial by Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I

“…The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive,…”
Get full text

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials by Hong, David S, DuBois, Steven G, Kummar, Shivaani, Farago, Anna F, Albert, Catherine M, Rohrberg, Kristoffer S, van Tilburg, Cornelis M, Nagasubramanian, Ramamoorthy, Berlin, Jordan D, Federman, Noah, Mascarenhas, Leo, Geoerger, Birgit, Dowlati, Afshin, Pappo, Alberto S, Bielack, Stefan, Doz, François, McDermott, Ray, Patel, Jyoti D, Schilder, Russell J, Tahara, Makoto, Pfister, Stefan M, Witt, Olaf, Ladanyi, Marc, Rudzinski, Erin R, Nanda, Shivani, Childs, Barrett H, Laetsch, Theodore W, Hyman, David M, Drilon, Alexander

“…The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary…”
Get full text

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial by Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W

“…Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is…”
Get full text

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial by Zhu, Andrew X, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Assenat, Eric, Brandi, Giovanni, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Motomura, Kenta, Ohno, Izumi, Merle, Philippe, Daniele, Bruno, Shin, Dong Bok, Gerken, Guido, Borg, Christophe, Hiriart, Jean-Baptiste, Okusaka, Takuji, Morimoto, Manabu, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi

“…Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of…”
Get full text

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial by Zhu, Andrew X, Finn, Richard S, Edeline, Julien, Cattan, Stephane, Ogasawara, Sadahisa, Palmer, Daniel, Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt, Sarker, Debashis, Verset, Gontran, Chan, Stephen L, Knox, Jennifer, Daniele, Bruno, Webber, Andrea L, Ebbinghaus, Scot W, Ma, Junshui, Siegel, Abby B, Cheng, Ann-Lii, Kudo, Masatoshi, Alistar, Angela, Asselah, Jamil, Blanc, Jean-Frederic, Borbath, Ivan, Cannon, Timothy, Chung, Ki, Cohn, Allen, Cosgrove, David P, Damjanov, Nevena, Gupta, Mukul, Karino, Yoshivasu, Karwal, Mark, Kaubisch, Andreas, Kelley, Robin, Van Laethem, Jena-Luc, Larson, Timothy, Lee, James, Li, Daneng, Manhas, Atisha, Manji, Gulam Abbas, Numata, Kazushi, Parsons, Benjamin, Paulson, Andrew S., Pinto, Carmine, Ramirez, Robert, Ratnam, Suresh, Rizell, Magnus, Rosmorduc, Olivier, Sada, Yvonne, Sasaki, Yutaka, Stal, Per I, Strasser, Simone, Trojan, Joerg, Vaccaro, Gina, Van Vlierberghe, Hans, Weiss, Alan, Weiss, Karl-Heinz, Yamashita, Tatsuya

“…Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety…”
Get full text

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial by Powles, Thomas, Oudard, Stephane, Vulsteke, Christof, Fléchon, Aude, Yu, Evan Y, Imai, Kentaro, Homet Moreno, Blanca, Alva, Ajjai, Lazzaro, Mauricio Fernandez, Gatica, Gabriela, Van Aelst, Filip, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Soares, Joao Paulo Holanda, Cheng, Susanna, Leal, Jose Luis, Ibanez, Carolina, Laguerre, Brigitte, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Gravis, Gwenaelle, Reichardt, Peter, Herden, Jan, Pfister, David, Niegisch, Guenter, Boegemann, Martin, Gakis, Georgios, Neisius, Andreas, Thomas, Christian, Kosa, Judit Erzsebet, Bodoky, Gyorgy, Geczi, Lajos, Frank, Stephen Jay, Kejzman, Daniel, Rosenbaum, Eli, Rouvinov, Keren, Arai, Gaku, Takayama, Tatsuya, Fujimoto, Kiyohide, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Takano, Toshimi, Joraku, Akira, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Beerepoot, Laurens, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Karlov, Petr Alexandrovich, Cohen, Graham Lawrence, Ruff, Paul, Lee, Nari, Rodriguez-Vida, Alejo, Grande, Enrique, Munoz Langa, Jose, Montesa Pino, Alvaro, Su, Wen-Pin, Chang, Yen-Hwa, Huang, Yi-Hsiu, Srimuninnimit, Vichien, Abali, Huseyin, Sendur, Mehmet Ali Nahit, Ozguroglu, Mustafa, Ozdogan, Mustafa, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Schlegel, Peter, Mamtani, Ronac, Wallace, James, Suh, Jason Jung-Gon, Burgess, Earle, Wong, John, Chaudhry, Arvind, Thomas, Christian A, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Joshi, Monika, Bolemon, Britt H, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Courtright, Jay G, Doshi, Gurjyot, Sartor, Oliver Alton, Mannuel, Heather D, Alva, Ajjai, Charles, Anthony, Ades, Steven, Yu, Evan, Fleming, Mark

“…PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are…”
Get full text